Instrument Name23Andme Holding Co.Instrument Symbol(ME-Q)

Instrument ExchangeNASDAQ

Most of the U.S. stock market edged lower after the Federal Reserve kicked off its efforts to prevent a recession with a bigger-than-usual cut to interest rates

The lawsuit accused the genetics testing company of failing to protect the privacy of 6.9 million customers whose personal information was exposed in a data breach last year

Business development companies can be a lucrative source of passive income.

Is altruism a good idea for an unprofitable capitalistic enterprise?

Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route.

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

Nu Holdings went from an idea to a $50 billion business over a handful of years. Several billionaire investors are betting on even more upside.

It's having trouble getting its core business model to work.

Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.

New York, New York--(Newsfile Corp. - December 7, 2023) - 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive data leak. The attack targeted the personal information of 23andMe users -more than 4 million people- compromising...

USA News Group – Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer’s...

Both businesses have a lot to prove.

Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings.

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

Neither has a traditional business model, but that could be an asset for both.

New opportunities are becoming apparent, but so are fresh risks in the biotech field.

/PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access,...

Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.

They've been using machine learning for years, and now they might do even more.

There's nothing better than getting a bargain that'll pay off for years.

Both are likely to double quite soon, and they aren't even that risky.

This healthcare company isn't without risk but is doing a good job executing on its vision.

Remember the SPAC boom? Here are seven products of that time that are still in my portfolio.

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

These stocks are all down 70% or more from what I paid.